Abcam and medx extend precision medicine strategic partnership

Cambridge, united kingdom and shanghai, china, april 12, 2021 (globe newswire) -- abcam (aim: abc; nasdaq: abcm), a global innovator in life science reagents and tools, and medx translational medicine (medx), formerly qiagen (suzhou) translational medicine co., ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for medx to supply to the chinese market.
ABCM Ratings Summary
ABCM Quant Ranking